Key Highlights
- 0.22 is the net loss per share in USD that ProPhase Labs, Inc. (OTCQB:PRPH) reported for the second quarter of 2026, compared with a net loss per share of USD 1.08 in the second quarter of 2025.
- 1.01 million is the quarterly Revenue in USD reported for the second quarter of 2026, down from USD 1.25 million a year earlier, a decline of about 19% (calculated), with no diagnostic services revenue recorded.
- 22.4% was the gross Margin in the second quarter of 2026, against 58.9% a year earlier, while general and administrative expense fell to USD 2.9 million from USD 4.6 million in the prior-year quarter.
- 95% is the technical validation success rate the company cites for its BE-Smart test, which it plans to commercialize as it moves away from diagnostic services toward genomics and consumer supplements.
What Investors Expect From ProPhase Labs, Inc. (OTCQB:PRPH) on November 16, 2026
ProPhase Labs is scheduled to report third quarter 2026 results on November 16, 2026, covering the quarter ended September 30, 2026. The prior-period comparison is the second quarter, when revenue was USD 1.01 million and net loss attributable to the parent was USD 3.05 million, or USD 0.22 per share. First quarter 2026 revenue was USD 478 thousand with a net loss of USD 0.43 per share, so quarterly revenue has stayed near USD 0.5 million to USD 1.0 million across the last two reports (calculated).
The Rationale: Last Reported Quarter and Management Outlook for ProPhase Labs, Inc. (OTCQB:PRPH)
The second quarter report, filed on August 19, 2026, showed net revenue of USD 1.01 million against USD 1.25 million a year earlier, driven by lower consumer supplement sales. Gross margin was 22.4% versus 58.9%, which the company tied to product mix. General and administrative expense declined to USD 2.9 million from USD 4.6 million on lower personnel, overhead and professional fees, and adjusted EBITDA from continuing operations was a loss of USD 561,000 versus a loss of USD 807,000. Management is expanding its Nebula and DNA Complete genomics offerings and plans to commercialize BE-Smart, while its diagnostic laboratory subsidiaries filed Chapter 11 and the company pursues receivable collections.
Valuation, Liquidity and Risks for ProPhase Labs, Inc. (OTCQB:PRPH)
On a trailing basis through June 30, 2026, revenue was USD 3.85 million, net loss was USD 22.46 million and diluted EPS was -1.71. Fiscal 2025 revenue was USD 4.35 million with a net loss of USD 14.74 million and EPS of -1.74, while fiscal 2024 revenue was USD 6.77 million with a net loss of USD 53.36 million and EPS of -26.68. Risks include the loss of diagnostic revenue, thin gross margin, Chapter 11 proceedings at the laboratory subsidiaries, uncertain receivable recoveries and the limited liquidity typical of over-the-counter shares.
Where Things Stand
ProPhase Labs, Inc. (OTCQB:PRPH) enters its November 16, 2026 report as a much smaller Business than in prior years, with trailing revenue of USD 3.85 million against USD 6.77 million in fiscal 2024. The second quarter loss narrowed to USD 3.05 million from USD 4.47 million, and general and administrative expense fell by USD 1.7 million (calculated). Investors will watch whether revenue, margin and cost control hold, how genomics and BE-Smart progress, and what the filing says about receivable collections and the Chapter 11 subsidiaries. This article is informational and is not Investment advice.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...